Top Track 250

In the past five years, Chiltern has conducted nearly 2,000 clinical trials for clients across the pharmaceutical, biotech and medical device and diagnostics sectors, with a focus on testing new cancer therapies. Chief executive Jim Esinhart, 53, oversees staff in 47 countries and saw sales at the Slough firm rise 36% to £217.8m in 2015, helped by the acquisition of American clinical research company Theorem for an undisclosed sum in September last year.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
CompanyChiltern International Group
ActivityContract research provider
Sales £m217.8
Operating profit £m25.0
Main shareholdersGalaxy Limited Partnership (representing a consolidated investment group of individuals) (90%), management (10%)

If applicable:

* supplied by Company   † annualised figure   ‡  profit = ebitda